Cargando…
Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice
Fucoxanthin is a marine carotenoid found in brown seaweeds and several microalgae. It has been reported that fucoxanthin has health benefits such as anti-obesity and anti-diabetic effects. To facilitate fucoxanthin applications in the food industry, it is important to improve its low bioavailability...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325202/ https://www.ncbi.nlm.nih.gov/pubmed/35877739 http://dx.doi.org/10.3390/md20070446 |
_version_ | 1784756991150784512 |
---|---|
author | Nagata, Kodai Takatani, Naoki Beppu, Fumiaki Abe, Aya Tominaga, Etsuko Fukuhara, Tomohisa Ozeki, Makoto Hosokawa, Masashi |
author_facet | Nagata, Kodai Takatani, Naoki Beppu, Fumiaki Abe, Aya Tominaga, Etsuko Fukuhara, Tomohisa Ozeki, Makoto Hosokawa, Masashi |
author_sort | Nagata, Kodai |
collection | PubMed |
description | Fucoxanthin is a marine carotenoid found in brown seaweeds and several microalgae. It has been reported that fucoxanthin has health benefits such as anti-obesity and anti-diabetic effects. To facilitate fucoxanthin applications in the food industry, it is important to improve its low bioavailability. We attempted the combined feeding of fucoxanthin-containing seaweed oil (SO) and monocaprin in a powder diet and analyzed the fucoxanthin metabolite contents in the liver, small intestine and serum of diabetic/obese KK-A(y) mice. After 4 weeks of feeding with the experimental diets, the serum fucoxanthinol concentrations of the mice fed 0.2% SO and 0.5% monocaprin were higher than those of the 0.2% SO-fed mice. Furthermore, fucoxanthinol accumulation in the liver and small intestine tended to increase in a combination diet of 0.2% SO and 0.125–0.5% monocaprin compared with a diet of 0.2% SO alone, although amarouciaxanthin A accumulation was not different among the 0.2% SO-fed groups. These results suggest that a combination of monocaprin with fucoxanthin-containing SO is an effective treatment for improving the bioavailability of fucoxanthin. |
format | Online Article Text |
id | pubmed-9325202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93252022022-07-27 Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice Nagata, Kodai Takatani, Naoki Beppu, Fumiaki Abe, Aya Tominaga, Etsuko Fukuhara, Tomohisa Ozeki, Makoto Hosokawa, Masashi Mar Drugs Communication Fucoxanthin is a marine carotenoid found in brown seaweeds and several microalgae. It has been reported that fucoxanthin has health benefits such as anti-obesity and anti-diabetic effects. To facilitate fucoxanthin applications in the food industry, it is important to improve its low bioavailability. We attempted the combined feeding of fucoxanthin-containing seaweed oil (SO) and monocaprin in a powder diet and analyzed the fucoxanthin metabolite contents in the liver, small intestine and serum of diabetic/obese KK-A(y) mice. After 4 weeks of feeding with the experimental diets, the serum fucoxanthinol concentrations of the mice fed 0.2% SO and 0.5% monocaprin were higher than those of the 0.2% SO-fed mice. Furthermore, fucoxanthinol accumulation in the liver and small intestine tended to increase in a combination diet of 0.2% SO and 0.125–0.5% monocaprin compared with a diet of 0.2% SO alone, although amarouciaxanthin A accumulation was not different among the 0.2% SO-fed groups. These results suggest that a combination of monocaprin with fucoxanthin-containing SO is an effective treatment for improving the bioavailability of fucoxanthin. MDPI 2022-07-07 /pmc/articles/PMC9325202/ /pubmed/35877739 http://dx.doi.org/10.3390/md20070446 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Nagata, Kodai Takatani, Naoki Beppu, Fumiaki Abe, Aya Tominaga, Etsuko Fukuhara, Tomohisa Ozeki, Makoto Hosokawa, Masashi Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice |
title | Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice |
title_full | Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice |
title_fullStr | Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice |
title_full_unstemmed | Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice |
title_short | Monocaprin Enhances Bioavailability of Fucoxanthin in Diabetic/Obese KK-A(y) Mice |
title_sort | monocaprin enhances bioavailability of fucoxanthin in diabetic/obese kk-a(y) mice |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325202/ https://www.ncbi.nlm.nih.gov/pubmed/35877739 http://dx.doi.org/10.3390/md20070446 |
work_keys_str_mv | AT nagatakodai monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice AT takataninaoki monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice AT beppufumiaki monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice AT abeaya monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice AT tominagaetsuko monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice AT fukuharatomohisa monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice AT ozekimakoto monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice AT hosokawamasashi monocaprinenhancesbioavailabilityoffucoxanthinindiabeticobesekkaymice |